Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference

Biophytis announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the American Thoracic Society International Conference (ATS 2023) that was held in Washington DC between the 19th and 24th of May 2023.

DR Girish Nair, MD – William Beaumont Hospital, Royal Oak, MI 48073, USA and principal investigator of the COVA study in the USA held an oral presentation of the results titled “COVA clinical study: Results from a double-blind, placebo-controlled phase 2-3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.”

Biophytis also presented a poster that will be available on Biophytis’ website.

ATS 2023 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. The American Thoracic Society is at the forefront of basic and translational respiratory science and is an essential event for all respiratory researchers. It offers a unique opportunity to present the results in front of well-recognized peers from across the globe.

Stanislas Veillet, CEO of Biophytis, said: “It was an honor to present these positive data to the scientific and medical community, showing a 44% reduction with Sarconeos (BIO101) vs placebo in the risk of respiratory failure or early death in hospitalized patients with severe COVID-19. This success is the result of the hard work of the clinical and medical teams involved in the COVA clinical study in France, Belgium, the USA and in Brazil. Sarconeos (BIO101) is the only innovative drug candidate in Europe or the United States targeting the Renin Angiotensin System (RAS), impaired by SARS-CoV-2, that has demonstrated clinical efficacy in a Phase 2-3 study, as well as a very good safety profile. We are now moving forward with preparing regulatory filings to apply for conditional Marketing Authorization (cMA) in Europe and Emergency Use Authorization (EUA) in the USA”.